• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

调节性 T 细胞对多发性骨髓瘤患者免疫抑制和疾病进展的贡献。

Contribution of regulatory T cells to immunosuppression and disease progression in multiple myeloma patients.

机构信息

Babak Myeloma Group; Department of Pathological Physiology; Faculty of Medicine; Masaryk University; Brno, Czech Republic.

出版信息

Oncoimmunology. 2013 Sep 1;2(9):e25619. doi: 10.4161/onci.25619. Epub 2013 Jul 9.

DOI:10.4161/onci.25619
PMID:24327932
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3850022/
Abstract

Multiple myeloma (MM) patients exhibit consistent degrees of immune dysfunction. Regulatory T cells contribute to the establishment of an immunosuppressive status in MM patients, hence favoring disease progression.

摘要

多发性骨髓瘤（MM）患者表现出一致程度的免疫功能障碍。调节性 T 细胞有助于 MM 患者建立免疫抑制状态，从而有利于疾病进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/161c/3850022/2b263f2075cb/onci-2-e25619-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/161c/3850022/2b263f2075cb/onci-2-e25619-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/161c/3850022/2b263f2075cb/onci-2-e25619-g1.jpg

相似文献

1
Contribution of regulatory T cells to immunosuppression and disease progression in multiple myeloma patients.调节性 T 细胞对多发性骨髓瘤患者免疫抑制和疾病进展的贡献。
Oncoimmunology. 2013 Sep 1;2(9):e25619. doi: 10.4161/onci.25619. Epub 2013 Jul 9.
2
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.靶向 CD38 抑制调节性 T 细胞的诱导和功能，减轻多发性骨髓瘤中的免疫抑制。
Clin Cancer Res. 2017 Aug 1;23(15):4290-4300. doi: 10.1158/1078-0432.CCR-16-3192. Epub 2017 Mar 1.
3
Myeloid-derived suppressor cells: The green light for myeloma immune escape.髓系来源的抑制性细胞：骨髓瘤免疫逃逸的绿灯
Blood Rev. 2016 Sep;30(5):341-8. doi: 10.1016/j.blre.2016.04.002. Epub 2016 Apr 12.
4
CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.在异基因干细胞移植后，CD4+CD25+FOXP3+调节性T细胞在多发性骨髓瘤患者的骨髓中重建并积聚。
Haematologica. 2008 Mar;93(3):423-30. doi: 10.3324/haematol.11897. Epub 2008 Feb 20.
5
Critical stoichiometric ratio of CD4(+)  CD25(+)  FoxP3(+) regulatory T cells and CD4(+)  CD25(-) responder T cells influence immunosuppression in patients with B-cell acute lymphoblastic leukaemia.B 细胞急性淋巴细胞白血病患者中 CD4(+)CD25(+)FoxP3(+)调节性 T 细胞与 CD4(+)CD25(-)应答性 T 细胞的临界化学计量比影响免疫抑制。
Immunology. 2014 May;142(1):124-39. doi: 10.1111/imm.12237.
6
Immunopathogenesis and immunotherapy of multiple myeloma.多发性骨髓瘤的免疫发病机制与免疫治疗
Int J Hematol. 2018 Mar;107(3):278-285. doi: 10.1007/s12185-018-2405-7. Epub 2018 Jan 24.
7
The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma.调节性 T 细胞的频率调节多发性骨髓瘤患者的生存：多发性骨髓瘤免疫状态的详细特征。
Br J Cancer. 2012 Jan 31;106(3):546-52. doi: 10.1038/bjc.2011.575. Epub 2012 Jan 5.
8
Immunoregulatory T cell function in multiple myeloma.多发性骨髓瘤中的免疫调节性T细胞功能
J Clin Invest. 1981 Mar;67(3):779-89. doi: 10.1172/JCI110095.
9
Regulatory T cells and multiple myeloma.调节性T细胞与多发性骨髓瘤
Clin Lymphoma Myeloma. 2008 Oct;8(5):283-6. doi: 10.3816/CLM.2008.n.039.
10
The role of suppressor cells in the pathogenesis of common variable hypogammaglobulinemia and the immunodeficiency associated with myeloma.抑制细胞在常见变异型低丙种球蛋白血症发病机制及与骨髓瘤相关免疫缺陷中的作用。
Fed Proc. 1976 Jul;35(9):2067-72.

引用本文的文献

1
Treg and Oligoclonal Expansion of Terminal Effector CD8 T Cell as Key Players in Multiple Myeloma.调节性 T 细胞和末端效应 CD8 T 细胞的寡克隆扩增作为多发性骨髓瘤的关键因素。
Front Immunol. 2021 Feb 23;12:620596. doi: 10.3389/fimmu.2021.620596. eCollection 2021.
2
Identification of the immune checkpoint signature of multiple myeloma using mass cytometry-based single-cell analysis.基于质谱流式细胞术的单细胞分析鉴定多发性骨髓瘤的免疫检查点特征
Clin Transl Immunology. 2020 Apr 29;9(5):e01132. doi: 10.1002/cti2.1132. eCollection 2020 May.
3
Mass Cytometry Discovers Two Discrete Subsets of CD39Treg Which Discriminate MGUS From Multiple Myeloma.

本文引用的文献

1
Flow cytometry based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment.来那度胺联合地塞米松治疗前后多发性骨髓瘤患者中基于流式细胞术的CD8调节性T细胞计数及功能特征分析
Cytometry B Clin Cytom. 2013 Jul 3. doi: 10.1002/cytob.21109.
2
Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment.功能抑制性 CD8+T 调节细胞在多发性骨髓瘤患者中增加：免疫损伤的原因。
PLoS One. 2012;7(11):e49446. doi: 10.1371/journal.pone.0049446. Epub 2012 Nov 13.
3
质谱细胞术发现两种离散的 CD39+Treg 亚群，可将 MGUS 与多发性骨髓瘤区分开来。
Front Immunol. 2019 Aug 2;10:1596. doi: 10.3389/fimmu.2019.01596. eCollection 2019.
4
Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients.来那度胺联合低剂量环磷酰胺和泼尼松可调节淋巴细胞中的IKAROS和AIOLOS，从而对来那度胺难治性多发性骨髓瘤患者产生免疫刺激作用。
Oncotarget. 2018 Sep 21;9(74):34009-34021. doi: 10.18632/oncotarget.26131.
5
Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model.使用基于混合多尺度智能体的模型预测联合疗法对骨髓瘤细胞生长的影响。
Oncotarget. 2017 Jan 31;8(5):7647-7665. doi: 10.18632/oncotarget.13831.
Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma.
调节性 T 细胞增多与多发性骨髓瘤的不良临床特征相关，并可预测疾病进展。
PLoS One. 2012;7(10):e47077. doi: 10.1371/journal.pone.0047077. Epub 2012 Oct 10.
4
Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent.多发性骨髓瘤中诱导调节性 T 细胞的肿瘤细胞生成是接触依赖性的，且与抗原呈递细胞无关。
PLoS One. 2012;7(5):e35981. doi: 10.1371/journal.pone.0035981. Epub 2012 May 29.
5
Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma.来那度胺与地塞米松联合诱导可增加既往未经治疗的多发性骨髓瘤患者的调节性细胞。
Leuk Lymphoma. 2012 Jul;53(7):1406-8. doi: 10.3109/10428194.2011.652106. Epub 2012 Jan 31.
6
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy.来那度胺对 NK 细胞功能的免疫刺激作用会被同时进行的地塞米松治疗显著抑制。
Blood. 2011 Feb 3;117(5):1605-13. doi: 10.1182/blood-2010-04-278432. Epub 2010 Oct 26.
7
Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.地塞米松与来那度胺协同抑制多发性骨髓瘤肿瘤生长，但降低了来那度胺诱导的 T 和 NK 细胞功能的免疫调节作用。
Curr Cancer Drug Targets. 2010 Mar;10(2):155-67. doi: 10.2174/156800910791054239.
8
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.多发性骨髓瘤的诊断、分期、风险分层及疗效评估标准。
Leukemia. 2009 Jan;23(1):3-9. doi: 10.1038/leu.2008.291. Epub 2008 Oct 30.
9
Specific control of immunity by regulatory CD8 T cells.调节性CD8 T细胞对免疫的特异性调控。
Cell Mol Immunol. 2005 Feb;2(1):11-9.